Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus☆
Introduction
Infection remains an important cause of mortality and morbidity in patients with systemic lupus erythematosus (SLE). Severe infection occurred in 11–45% of SLE patients depending on case definition, study population, observation period, etc. [1], [2], [3], [4], [5], [6], [7]. Although several centers reported their incidence of infection, specific studies on severe infection from large, multicenter SLE cohorts are lacking. Roughly 30% of deaths in SLE patients are related to infections and recent data from a multicenter French registry suggest that overall mortality for infectious diseases in SLE is higher than thought [8]. Additionally, severe infections account for 11–23% of all hospitalization in SLE patients [3], [9], [10], with hospitalization rates for serious infections 12 times higher than that in patients without SLE [11], thus forming a significant part of the direct health-related costs associated with SLE [12].
Several factors are associated with a predisposition to infection in SLE patients, including disease-related factors, immunosuppressant and corticosteroid use, and intrinsic immune deregulations [13], [14], [15]. However, the relative contribution of each is not well known and comprehensive infection risk factor analysis is lacking. To determine the density of incidence of severe infection, delineate any associated factors and explore its clinical impact, we analyzed cumulative infection data from the RELESSER-T registry (Spanish Society of Rheumatology Lupus Registry—retrospective phase), a very large, non-selected multicenter and well-characterized SLE patient cohort containing abundant data on comorbidities [16].
Section snippets
Methods
Patients from the RELESSER-T registry who met at least 4 ACR-97 SLE criteria were included. The variables, definitions, processes, and methodological characteristics of the registry have been previously described in detail [17], [18]. In short, RELESSER-T is a multicenter, hospital-based registry, with retrospective cross-sectional collection of data from a large representative sample of adult non-selected patients with SLE attending Spanish rheumatology services from the public national health
Results
A total of 3658 SLE patients were included, 90% female, median age 32.9 years, and interquartile range (IQR): 19.4. Regarding ethnic distribution, 93% were Caucasian, 5% Hispanic (Latin-American: Amerindian or Mestizo) (N = 185) and less than 1% other ethnic groups. Mean follow-up (months) was 120.2 (SD = ±87.6, range: 508).
The main clinical characteristic of the cohort has been extensively described elsewhere [15]. The ACR97 SLE criteria distribution are shown in Table 1. The median S-SLEDAI
Discussion
The incidence of severe infection in SLE patients in the RELESSER registry (19.3%) was not very different than previous reports involving other large cohorts [4], [9], [21], [22], although certainly lower than in previous studies from monocentric cohorts in Spain, ranging from 29% to 38% [23], [24], or than was recently reported by Feldman et al. [25] in a study involving an extensive administrative SLE database from the United States. Differences in patient selection and/or time of follow-up
Conclusions
Our results need to be confirmed in prospective studies; specifically, with a more exhaustive inclusion of variables related to infection. Nonetheless, several remarkable conclusions can be drawn from our data:
- (1)
Severe infection is associated with severity and damage in SLE patients. There are ethnic differences in the prevalence of infection in SLE, with rates appearing to be higher in Latin-Americans.
- (2)
Respiratory bacterial infections are the most commonly found severe infection in SLE, although
Acknowledgments
We are grateful to all of the employees of the Spanish Rheumatology Society Research Unit for their commitment and professionalism.
References (58)
- et al.
Immunopathogenesis and spectrum of infections in systemic lupus erythematosus
Semin Arthritis Rheum
(1996) - et al.
Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study
Rev Clin Esp (Barc)
(2013) Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis
Best Pract Res Clin Rheumatol
(2002)- et al.
Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus
Rheum Dis Clin North Am
(2009) - et al.
National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology
Reumatol Clin
(2014) - et al.
Severe infections in a cohort of patients with systemic lupus erythematosus
(2010) Infection in systemic lupus erythematosus
Rheum Dis Clin North Am
(1998)- et al.
Tuberculosis in a cohort of patients with systemic lupus erythematosus
Reumatol Clin
(2010) - et al.
Tobacco smoking increases the risk for death from pneumococcal pneumonia
Chest
(2014) - et al.
Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century
Int J Antimicrob Agents
(2007)
Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1
Lancet
Effects of chloroquine on viral infections: an old drug against today׳s diseases?
Lancet Infect Dis
Inadequate antimicrobial treatment for nosocomial infection is a mortality risk factor for systemic lupus erythematous patients admitted to intensive care unit
Am J Med Sci
Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus
Ann Rheum Dis
Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality
Lupus
Morbidity and mortality in systemic lupus erythematosus. A multicenter prospective study of 1000 patients
Medicine (Baltimore)
A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value
Clin Rheumatol
Systemic lupus erythematosus. Follow-up study of 148 patients. II: predictive factors of importance for course and outcome
Clin Rheumatol
Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico city
Clin Exp Rheumatol
Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis
Arthritis Rheumatol
Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort
J Rheumatol
Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome
Lupus
Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011
Arthritis Care Res (Hoboken)
Clinical and immunogenetic factors associated with pneumonia in patients with systemic lupus erythematosus: a case–control study
J Rheumatol
Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences
Medicine (Baltimore)
Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus
Lupus
A simple severity of disease index for systemic lupus erythematosus
Lupus
Understanding Cox׳s regression model
Experientia
Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus
Arthritis Rheum
Cited by (0)
- ☆
Financial supporters: Spanish Foundation of Rheumatology. FIS/ISCIII (Grant no. PI11/02857). Dr. Pego-Reigosa is supported by Grant 316265 (BIOCAPS) from the European Union 7th Framework Programe (FP7/REGPOT-2012–2013.1).